Cargando…
Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with a variable course, and remains an incurable disease. Frequent relapses and eventual resistance to fludarabine characterize symptomatic CLL and portends a dismal prognosis for patients. Growing evidence has shown that signaling pathwa...
Autores principales: | Chavez, Julio C, Sahakian, Eva, Pinilla-Ibarz, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662532/ https://www.ncbi.nlm.nih.gov/pubmed/23717217 http://dx.doi.org/10.2147/CE.S34068 |
Ejemplares similares
-
The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?
por: Gamal, Wael, et al.
Publicado: (2022) -
Role of ofatumumab in treatment of chronic lymphocytic leukemia
por: Veliz, Marays, et al.
Publicado: (2011) -
Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia
por: Khan, Maliha, et al.
Publicado: (2017) -
Electrocardiographic Changes Associated With Ibrutinib
Exposure
por: Fradley, Michael G., et al.
Publicado: (2020) -
Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
por: Puła, Bartosz, et al.
Publicado: (2019)